Literature DB >> 17379085

Management of radiation-induced nausea and vomiting.

George G Abdelsayed1.   

Abstract

Management of radiation-induced nausea and vomiting (RINV) includes both prevention and therapy. Primary prevention involves implementation of measures to modify risk factors. Secondary prevention involves prophylaxis and treatment with 5HT(3) receptor antagonists (5HT(3)RAs) with or without corticosteroids, dopamine antagonists, antihistamines, or anticholinergics. 5HT(3)RAs are also useful in treatment of RINV with significantly better outcomes, compared to other antiemetics or placebo. Agents include ondansetron, granisetron, dolasetron, palonosetron, and tropisitron. These agents may be useful in both the radiotherapy patient and the individual who has been accidentally exposed to ionizing radiation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17379085     DOI: 10.1016/j.exphem.2007.01.010

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  6 in total

1.  Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ).

Authors:  Mary Lou Affronti; Sarah Woodring; Karen Allen; John Kirkpatrick; Katherine B Peters; James E Herndon; Frances McSherry; Patrick N Healy; Annick Desjardins; James J Vredenburgh; Henry S Friedman
Journal:  Support Care Cancer       Date:  2016-06-06       Impact factor: 3.603

Review 2.  Literature review and global consensus on management of acute radiation syndrome affecting nonhematopoietic organ systems.

Authors:  Nicholas Dainiak; Robert Nicolas Gent; Zhanat Carr; Rita Schneider; Judith Bader; Elena Buglova; Nelson Chao; C Norman Coleman; Arnold Ganser; Claude Gorin; Martin Hauer-Jensen; L Andrew Huff; Patricia Lillis-Hearne; Kazuhiko Maekawa; Jeffrey Nemhauser; Ray Powles; Holger Schünemann; Alla Shapiro; Leif Stenke; Nelson Valverde; David Weinstock; Douglas White; Joseph Albanese; Viktor Meineke
Journal:  Disaster Med Public Health Prep       Date:  2011-10-10       Impact factor: 1.385

3.  Moderate to severe nausea in radioactive iodine (RAI) therapy is associated with the RAI dose per body weight and was not prevented by ramosetron.

Authors:  Toshiyuki Ikeoka; Takao Ando; Misa Imaizumi; Ikuko Ueki; Toshiro Usa; Atsushi Kawakami
Journal:  Endocrine       Date:  2014-05       Impact factor: 3.633

4.  Ondansetron rapidly dissolving film for the prophylactic treatment of radiation-induced nausea and vomiting-a pilot study.

Authors:  E Wong; N Pulenzas; G Bedard; C DeAngelis; L Zhang; M Tsao; C Danjoux; N Thavarajah; B Lechner; R McDonald; P M Cheon; E Chow
Journal:  Curr Oncol       Date:  2015-06       Impact factor: 3.677

5.  One third of patients with radiotherapy-induced nausea consider their antiemetic treatment insufficient.

Authors:  Anna Enblom; Beata Bergius Axelsson; Gunnar Steineck; Mats Hammar; Sussanne Börjeson
Journal:  Support Care Cancer       Date:  2008-06-05       Impact factor: 3.603

6.  Use of granisetron transdermal system in the prevention of chemotherapy-induced nausea and vomiting: a review.

Authors:  Albert Tuca
Journal:  Cancer Manag Res       Date:  2009-12-16       Impact factor: 3.989

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.